Bristol-Myers Squibb Co vs Clear Secure Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.95 (market cap $116.30B), while Clear Secure Inc trades at $54.33 (market cap $5.39B). The key difference: Bristol-Myers Squibb Co is far larger — about 21.6× Clear Secure Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | YOU | |
|---|---|---|
Market Cap | $116.30B | $5.39B |
Sector | Health | Technology |
52-Week High | $62.37 | $62.36 |
52-Week Low | $42.60 | $28.84 |
Enterprise Value | $152.24B | $4.71B |
Dividend Yield | 4.42% | 1.12% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Clear Secure (YOU) trades at $53.08, down 3.88% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 65.48% gross margins and impressive 81.15% ROE. Recent Q1 2026 earnings beat expectations at $0.38 EPS versus $0.35 expected, while analysts maintain a mixed consensus with 44% buy ratings and a $56.67 price target. The company continues expanding its airport security services with recent launches in Indianapolis and Miami.
YOU presents a compelling growth story with expanding revenue and profitability, though elevated valuation multiples (P/E 42.83) warrant caution. Near-term catalysts include Q2 earnings and continued airport expansion, while risks involve execution challenges and market volatility. The stock offers potential upside to analyst targets but requires monitoring of earnings consistency.
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →